ASCO 2025 | Targeting tumor-wide RNA splicing aberrations as neoantigens
Darwin Kwok
• 31 May 2025
Darwin Kwok, PhD, University of California, San Francisco, CA, discusses the development of a neoantigen discovery platform that identifies splicing-derived neoantigens across multiple cancer types. Using transcriptomic and proteomic datasets, the study highlights public, clonally-expressed neojunctions with potential for immunotherapeutic targeting. The findings support aberrant splicing as a promising neoantigen source. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
